|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q87920448
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010740.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q87920448
|
|
024
|
|
|
‡a
0000-0001-7940-0194
‡2
orcid
|
|
024
|
|
|
‡a
33267449500
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q87920448
|
|
100
|
0 |
|
‡a
Monica Alves
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Monica Alves
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Corneal blindness in Plato's cave: the acting forces to prevent and revert corneal opacity. Part I: epidemiology and new physiopathological concepts
|
|
670
|
|
|
‡a
Author's Impact of conjunctival autograft on pterygium treatment: evaluation of related symptoms and patients' satisfaction after surgery.
|
|
670
|
|
|
‡a
Author's Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
|
|
670
|
|
|
‡a
Author's Impact of pterygium on the ocular surface and meibomian glands
|
|
670
|
|
|
‡a
Author's Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests
|
|
670
|
|
|
‡a
Author's Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo
|
|
670
|
|
|
‡a
Author's Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
|
|
670
|
|
|
‡a
Author's Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial
|
|
670
|
|
|
‡a
Author's TFOS DEWS II Epidemiology Report
|
|
909
|
|
|
‡a
(orcid) 0000000179400194
‡9
1
|
|
909
|
|
|
‡a
(scopus) 33267449500
‡9
1
|
|
919
|
|
|
‡a
tfosdews2epidemiologyreport
‡A
TFOS DEWS II Epidemiology Report
‡9
1
|
|
919
|
|
|
‡a
issjogrenssyndromedryeyesimilartodryeyecausedbyotheretiologiesdiscriminatingdifferentdiseasesbydryeyetests
‡A
Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests
‡9
1
|
|
919
|
|
|
‡a
impactofocularsurfacediseasetreatmentinpatientswithglaucoma
‡A
Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
‡9
1
|
|
919
|
|
|
‡a
impactofconjunctivalautograftonpterygiumtreatmentevaluationofrelatedsymptomsandpatientssatisfactionaftersurgery
‡A
Impact of conjunctival autograft on pterygium treatment: evaluation of related symptoms and patients' satisfaction after surgery.
‡9
1
|
|
919
|
|
|
‡a
oculargraftversushostdiseaseafterhematopoieticcelltransplantationexpertreviewfromthelateeffectsandqualityoflifeworkingcommitteeofthecenterforinternationalbloodandmarrowtransplantresearchandtransplantcomplicationswo
‡A
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo
‡9
1
|
|
919
|
|
|
‡a
oculargraftversushostdiseaseafterhematopoieticcelltransplantationexpertreviewfromthelateeffectsandqualityoflifeworkingcommitteeofthecibmtrandtransplantcomplicationsworkingpartyoftheebmt
‡A
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
‡9
1
|
|
919
|
|
|
‡a
impactofpterygiumontheocularsurfaceandmeibomianglands
‡A
Impact of pterygium on the ocular surface and meibomian glands
‡9
1
|
|
919
|
|
|
‡a
safetyandefficacyofintracameralmoxifloxacinforpreventionofpostcataractendophthalmitisrandomizedcontrolledclinicaltrial
‡A
Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial
‡9
1
|
|
919
|
|
|
‡a
cornealblindnessinplatoscavetheactingforcestopreventandrevertcornealopacitypart1epidemiologyandnewphysiopathologicalconcepts
‡A
Corneal blindness in Plato's cave: the acting forces to prevent and revert corneal opacity. Part I: epidemiology and new physiopathological concepts
‡9
1
|
|
996
|
|
|
‡2
PTBNP|1485741
|
|
996
|
|
|
‡2
LC|n 2007206871
|
|
996
|
|
|
‡2
BLBNB|001486721
|
|
996
|
|
|
‡2
BLBNB|000568049
|
|
996
|
|
|
‡2
LC|n 93020707
|
|
996
|
|
|
‡2
BNC|981058601557406706
|
|
996
|
|
|
‡2
ISNI|0000000068411843
|
|
996
|
|
|
‡2
ISNI|000000004045047X
|
|
996
|
|
|
‡2
ISNI|0000000069425809
|
|
996
|
|
|
‡2
PTBNP|3430
|
|
996
|
|
|
‡2
ISNI|0000000068713585
|
|
996
|
|
|
‡2
NTA|381183793
|
|
996
|
|
|
‡2
PTBNP|3596
|
|
996
|
|
|
‡2
PTBNP|940329
|
|
996
|
|
|
‡2
ISNI|0000000070732945
|
|
996
|
|
|
‡2
ISNI|0000000068777669
|
|
996
|
|
|
‡2
LC|n 2014013887
|
|
996
|
|
|
‡2
ISNI|0000000043598920
|
|
996
|
|
|
‡2
BLBNB|001495210
|
|
996
|
|
|
‡2
ISNI|0000000428221139
|
|
996
|
|
|
‡2
LC|no2004121870
|
|
996
|
|
|
‡2
BLBNB|000596914
|
|
996
|
|
|
‡2
DNB|1056590289
|
|
996
|
|
|
‡2
NSK|000712105
|
|
996
|
|
|
‡2
DNB|1017717915
|
|
996
|
|
|
‡2
ISNI|0000000069509447
|
|
996
|
|
|
‡2
PTBNP|196214
|
|
996
|
|
|
‡2
ISNI|0000000070736575
|
|
996
|
|
|
‡2
NUKAT|nx2022971307
|
|
996
|
|
|
‡2
PTBNP|1691420
|
|
996
|
|
|
‡2
BLBNB|000273245
|
|
996
|
|
|
‡2
PTBNP|75612
|
|
996
|
|
|
‡2
ISNI|0000000031471551
|
|
996
|
|
|
‡2
PTBNP|3605
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
